Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 14(1); 2014 > Article
Review Article Radioembolization in Hepatocellular Carcinoma
Ho Jong Chun
Journal of Liver Cancer 2014;14(1):1-6
DOI: https://doi.org/10.17998/jlc.14.1.1
Published online: March 31, 2014
  • 680 Views
  • 17 Download
  • 0 Crossref
  • 0 Scopus
Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
Corresponding author:  Ho Jong Chun,
Email: chunray@catholic.ac.kr

Radioembolization is an emerging treatment modality in patients with hepatocellular carcinoma (HCC) and is a form of brachytherapy in which intra-arterially injected Ytrrium-90 microspheres are used for internal radiation purpose. Ytrrium-90 is a high energy beta particle-emitting radioisotope. Ytrrium-90 microspheres administered via arterial route direct the highly concentrated radiation to the tumor while normal liver parenchyma is relatively spared due to its preferential blood supply from portal venous blood. Main complications do not result from the microembolic effect, even in patients with portal vein thrombosis, but rather from an excessive irradiation to the non-target tissues including the liver. All the evidence that support the use of radioembolization in HCC is based on retrospective series or non-controlled prospective studies. However, reliable data can be obtained from the literature, particularly since the recent publication of large series. When compared to the standard of treatment for the intermediate and advanced stages (TACE and sorafenib), radioembolization consistently provides similar survival rates. Many randomized controlled trials using radioembolization are underway and will provide optimal evidences as standard treatment for unresectable HCC.


JLC : Journal of Liver Cancer